11 studies found for:    "X-linked agammaglobulinemia"
Show Display Options
RSS Create an RSS feed from your search for:
"X-linked agammaglobulinemia"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinemia;   Hyper-IgM Syndrome;   Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex
2 Unknown  Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
Conditions: X-Linked Agammaglobulinemia;   X-Linked Hyper IgM Syndrome;   Wiskott-Aldrich Syndrome;   Leukocyte Adhesion Deficiency Syndrome
Intervention:
3 Terminated Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Conditions: Immunologic Deficiency Syndromes;   Chediak-Higashi Syndrome;   Common Variable Immunodeficiency;   Graft Versus Host Disease;   X-Linked Lymphoproliferative Syndrome;   Familial Erythrophagocytic Lymphohistiocytosis;   Hemophagocytic Lymphohistiocytosis;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   X-linked Hyper IgM Syndrome;   Severe Combined Immunodeficiency;   Leukocyte Adhesion Deficiency Syndrome;   Virus-Associated Hemophagocytic Syndrome
Interventions: Drug: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Procedure: Allogeneic Bone Marrow Transplantation
4 Suspended Pharmacokinetics (PK) and Safety of Subgam®VF in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyper-Immunoglobulin M (IgM0Syndrome
Intervention: Biological: Subgam
5 Not yet recruiting Mutation of the BTK Gene and Genotype-phenotype Correlation of Chinese Patients With X-Linked Agammaglobulinemia
Condition: Agammaglobulinemia, BTK
Intervention:
6 Completed
Has Results
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy
Conditions: Common Variable Immunodeficiency;   X-linked Agammaglobulinemia;   Autosomal Recessive Agammaglobulinemia
Intervention: Biological: Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)
7 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
8 Recruiting Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases
Conditions: Primary Immune Deficiency Disorders;   Common Variable Immunodeficiency;   X-linked Agammaglobulinaemia;   Hyper-IgM Syndrome
Interventions: Biological: Gammaplex (5%);   Biological: Gammaplex 10
9 Completed Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds
Condition: Nasolabial Folds
Intervention: Drug: Hyaluronic acid filler/IMD1 basic
10 Completed
Has Results
Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency
Conditions: Common Variable Immunodeficiency;   Agammaglobulinemia
Intervention: Drug: Vivaglobin
11 Completed A Clinical Study of Intravenous Immunoglobulin
Condition: Immunologic Deficiency Syndromes
Intervention: Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV

Indicates status has not been verified in more than two years